© 2021 MJH Life Sciences and Contagion Live. All rights reserved.
© 2021 MJH Life Sciences™ and Contagion Live. All rights reserved.
September 18, 2021
Considerations for switching therapies used to manage patients with HIV following resistance or progression on prior treatment.
Drs Osama Hamdy and Tavell Kindall react to the association between weight gain and antiretroviral therapies used to treat HIV.
September 15, 2021
Higher HIV viral loads and additional heart disease factors increase the risk as well.
September 13, 2021
A small subset of people living with HIV (PLWH) can naturally suppress the virus without medication.
Changes in perceptions about the severity of HIV with advances in treatment and efforts to normalize living with the disease may create challenges for HIV prevention, a new study from the Netherlands suggests.
September 11, 2021
A discussion regarding the safety profile and use of bictegravir/emtricitabine/tenofovir alafenamide as treatment for HIV.
Interpretations of data supporting the use of single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide as treatment for patients with HIV and its effects on patient weight.
September 10, 2021
Islatravir exerts multiple mechanisms against HIV, demonstrates treatment effectiveness with doravirine, and is a potential weekly or monthly oral PrEP.
September 07, 2021
HIV coinfection was associated with a 3.7-fold increase in the risk of non-liver-related cancer among patients with hepatitis C virus infection, a new study found.
Optimizing delivery of HIV preexposure prophylaxis will take more than access to health care, according to a recent analysis of PrEP use behaviors among adults in an integrated health system.